Insmed (INSM) Net Income Growth (3y) (2013 - 2026)

Insmed (INSM) Net Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 6.30%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 10.23%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 72.22%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 37.89%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 25.99%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -38.56%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 37.44%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 62.15%
10 Roivant Sciences 26.16 Bn 26.85 Bn 1.16 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2026 62.15%
Mar 31, 2026 -0.79%
Dec 31, 2025 -27.06%
Sep 30, 2025 -41.30%
Jun 30, 2025 -49.83%
Mar 31, 2025 -39.45%
Dec 31, 2024 -27.77%
Sep 30, 2024 -25.07%
Jun 30, 2024 -36.84%
Mar 31, 2024 -19.70%
Dec 31, 2023 -22.11%
Sep 30, 2023 -35.66%
Jun 30, 2023 -58.20%
Mar 31, 2023 -34.05%
Dec 31, 2022 -44.55%
Sep 30, 2022 -29.32%
Jun 30, 2022 -12.87%
Mar 31, 2022 -8.47%
Dec 31, 2021 -7.24%
Sep 30, 2021 -8.71%